Le Cyclone® IKON est le cyclotron haute énergie et haute capacité d'IBA qui offre le plus grand spectre d'énergie pour la production d’isotopes TEP et TEMP de 13 MeV à 30 MeV.

In addition, Augustine today announced the founding of a Copenhagen, Denmark based subsidiary, Augustine Therapeutics Denmark ApS, which will serve as the company’s hub for research related to ...

Orion’s collaborator, MSD, expands clinical development program for opevesostat to women’s cancers ...

The Cyclone® IKON is IBA’s high energy and high-capacity cyclotron which offers the largest energy spectrum for the production of PET and SPECT isotopes from 13 MeV to 30 MeV ...

Beyond 2027, Idorsia aims to continue the sales trajectory of QUVIVIQ with a stable OPEX, leading to higher sustainable profitability. This could benefit from additional income from new collaborations ...

Groundbreaking procedures extend ONWARD’s leadership in the rapidly emerging brain-computer interface (BCI) field ARC-BCI Therapy is designed to restore thought-driven movement after spinal cord ...

SYNDEO Medical is highly differentiated in the marketplace by integrating everyday-use diagnostic and interventional products—typically procured separately—into custom-designed interventional ...

TEL AVIV, Israel, May 20, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals (NYSE and TASE: TEVA) today announced that Fitch Ratings Agency (“Fitch”) has raised the Company's corporate credit rating to ...

TrialWire is the AI and algorithm-powered patient-recruitment and enrollment platform, purpose-built on Salesforce Health Cloud to guarantee best-in-class data and IP security.

The Global Alzheimer’s Platform Foundation® (GAP) applauds the FDA's clearance of the first blood test to diagnose Alzheimer’s disease. Fujirebio’s Lumipulse G pTau217/ß-Amyloid 1-42 Plasma Ratio ...

Oslo, 20 May 2025. PCI Biotech Holding ASA ("PCI Biotech" or the "Company") issue this notification on behalf of Hans Peter Bøhn, Chair of the Board of Directors.

This major step unlocks a new milestone payment of €26.5 million under our Licensing and Collaboration Agreement with Ipsen 2, due upon pricing and reimbursement of Iqirvo® (elafibranor) in three ...